It was reported yesterday that India-based Dr Reddy's Laboratories Ltd (BSE: 500124)( NSE: DRREDDY)( NYSE: RDY) along with its subsidiaries have revealed positive topline results from its Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis.

In the study, the product met both co-primary endpoints after 24 weeks of oral treatment. Safety and efficacy data from the study will be presented in future dermatology conferences.

PPC-06 is an extended release formulation of a fumaric acid ester, in-licensed from Xenoport, Incorporated for further development to treat moderate to severe plaque psoriasis.

A Phase 2b clinical study was conducted to assess the tolerability, safety and efficacy of three doses of PPC-06 over 24 weeks, conducted at 76 sites in the United States. The co-primary end points of the study were the proportion of treated subjects achieving a 75% reduction in their PASI score over baseline, and IGA score of zero or one at week 24.